TNFSF13B and juvenile dermatomyositis: JDM patients with evidence of oligoclonal B cell expansion prior to Rituximab therapy (as demonstrated by an elevated CJ:KREC ratio) had a more favorable clinical response to Rituximab, and these patients also showed an increase in serum BAFF levels after Rituximab23.